Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in Humans

Infectious Disorders - Drug Targets

Volumn 14, Issue 1, 2014, Pages 37-43

  Strayer, David R ^a   Dickey, Robert ^a,b   Carter, William A ^a  

^a HEMISPHERX BIOPHARMA INC   (United States)

^b Caladrius Biosciences   (United States)

Author keywords

Antivirals; Cmax; Coronaviruses; EC50; IC50; Interferons; MERS; SARS

Indexed keywords

ALPHA2B INTERFERON; ALPHAN1 INTERFERON; ALPHAN3 INTERFERON; BETA1A INTERFERON; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; GAMMA1B INTERFERON; INTERFERON; INTERFERON BETA SERINE; INTERFERON INDUCING AGENT; MYCOPHENOLIC ACID; NEUTRALIZING ANTIBODY; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN; RINTATOLIMOD; TOLL LIKE RECEPTOR AGONIST; ANTIVIRUS AGENT; IMMUNOLOGIC FACTOR;

ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CYTOPATHOGENIC EFFECT; DISEASE MODEL; DRUG ACTIVITY; EC50; HUMAN; IC50; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; SARS CORONAVIRUS; SEROCONVERSION; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS DETECTION; ANIMAL; BLOOD; CELL LINE; CORONAVIRUS INFECTIONS; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; PATHOGENICITY; RESPIRATORY TRACT MUCOSA; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CORONAVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERONS; MICROBIAL SENSITIVITY TESTS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; RESPIRATORY MUCOSA; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 84917734535     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/1871526514666140713152858     Document Type: Article

References (43)

1. http://www.who.int/csr/don/2014_06_14_mers/en/
2. Josset, L.; Menacheryb, V.D.; Gralinskib, L.E.; Agnihothramb, S.; Sovaa, P.; Cartera, V.S.; Yountb, B.L.; Grahamb, R. L.; Baricb, R.S.; Katzea, M.G. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. Mbio, 2013, 4(3), e00165-13.
3. Graham, R.L; Donaldson, E.F.; Baric, R.S. A decade after SARS: strategies for controlling emerging coronaviruses. Nature Reviews Microbiology, 2013, 11, 836–48.
4. Chan, J.F.; To, K.K.; Tse, H.; Jin, D.Y.; Yuen, K.Y. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol, 2013, 21(10), 544-55.
5. Hilgenfeld, R; Peiris, M. From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. Antiviral Research, 2013, 100(1), 286-95.
6. Chan, J.F.; Chan, K.H.; Choi, G.K.; To, K.K.; Tse, H.; Cai, J.P.; Yeung, M.L.; Cheng, V.C.; Chen, H.; Che, X.Y.; Lau, S.K.; Woo, P.C.; Yuen, K.Y. Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications on disease pathogenesis and clinical manifestation. J Infect Dis, 2013, doi:10.1093/infdis/jit123.
7. Zhao, Q.; Weber, E.; Yang, H. Drug targets for rational design against emerging coronaviruses. Infect Disord Drug Targets, 2013, 13(2), 116-27.
8. Müller, M.A.; Raj, V.S.; Muth, D.; Meyer, B.; Kalliesa, S.; Smits, S.L.; Wollnya, R.; Bestebroer, T.M.; Specht, S.; Suliman, T.; Zimmermann, K.; Binger, T.; Eckerle, I.; Tschapka, M.; Zaki, A.M.; Osterhaus, A.D.M.E.; Fouchier, R.A.M.; Haagmans, B.L.; Drosten, C. Human coronavirus EMC does not require the SARScoronavirus receptor and maintains broad replicative capability in mammalian cell lines. MBio, 2012, 3(6), e00515-12. doi:10.1128/mBio.00515-12.
9. Raj, V.S.; Mou, H.; Smits, S.L.; Dekkers, D.H.; Müller, M.A.; Dijkman, R.; Muth, D.; Demmers, J.A.; Zaki, A.; Fouchier, R.A.; Thiel, V.; Drosten, C.; Rottier, P.J.; Osterhaus, A.D.; Bosch, B.J.; Haagmans, B.L. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature, 2013, 495, 251-4.
10. Barnard, D.L.; Day, C.W.; Bailey, K.; Heiner, M.; Montgomery, R.; Lauridsen, L.; Chan, P.K.; Sidwell, RW. Evaluation of immunomodulators, interferons and known in vitro SARS-CoV inhibitors for inhibition of SARS-CoV replication in BALB/c mice. Antivir Chem Chemother, 2006, 17(5), 275-84.
11. Day, C.W.; Baric, R.; Cai, S.X.; Frieman, M.; Kumaki, Y.; Morrey, J.D.; Smee, D.F.; Barnard, D.L. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology, 2009, 395(2), 210-22.
12. Tan, E.L.; Ooi, E.E.; Lin, C.Y.; Tan, H.C.; Ling, A.E.; Lim, B.; Stanton, L.W. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis, 2004, 10(4), 581-6.
13. Dahl, H.; Linde, A.; Strannegård, O. In vitro Inhibition of SARS Virus Replication by Human Interferons. Scand J Infect Dis, 2004, 36(11-12), 829-31.
14. Cinatl, J.; Morgenstern, B.; Bauer, G.; Chandra, P.; Rabenau, H.; Doerr, HW. Treatment of SARS with human interferons. Lancet, 2003, 362, 293-94.
15. Chan, J.F.W.; Chan, K-H.; Kao, R.Y.T; To, K.K.W.; Zheng, B-J.; Li C.P.Y; Li P.T.W; Dai, J; Mok, F.K.Y.; Chen, H; Hayden, F.G.; Yuen, K-Y. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect, 2013, 67, 606-616.
16. Morgenstern, B.; Michaelis, M.; Baer, P.C.; Doerr, H.W.; Cinatl, J. Jr. Ribavirin and interferon-b synergistically inhibit SARSassociated coronavirus replication in animal and human cell lines. Biochem and Biophys Res Comm, 2005, 326, 905-8.
17. Strayer, D.; Carter, W. Recombinant and Natural Human Interferons: Analysis of the Incidence and Clinical Impact of Neutralizing Antibodies. J IFN Cytokine Res, 2012, 32(3):95-102.
18. de Wilde, A.H.; Raj, V.S.; Oudshoorn, D.; Bestebroer, T.M.; van Nieuwkoop, S.; Limpens, R.W.; Posthuma, C.C.; van der Meer, Y.; Bárcena, M.; Haagmans, B.L.; Snijder, E.J.; van den Hoogen, B.G. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment. J Gen Virol, 2013, 94(8), 1749-60.
19. Tao, X.; Hill, T.E.; Morimoto, C.; Peters, C.J.; Ksiazek, T.G.; Tseng, C.T. Bilateral Entry and Release of Middle East Respiratory Syndrome-Coronavirus Induces Profound Apoptosis of Human Bronchial Epithelial Cells. J Virol, 2013, 3 July doi:10.1128/JVI.01562-13.
20. Kindler, E.; Jónsdóttir, H.R.; Muth, D.; Hamming, O.J.; Hartmann, R.; Rodriguez, R.; Geffers, R.; Fouchier, R.A.; Drosten, C.; Müller, M.A.; Dijkman, R.; Thiel, V. Efficient replication of the novel human betacoronavirus EMC on primary human epithelium highlights its zoonotic potential. MBio, 2013, 4(1), e00611-12.
21. Zielecki, F.; Weber, M.; Eickmann, M.; Spiegelberg, L.; Zaki, A.M.; Matrosovich, M.; Becker, S.; Weber, F. Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus. J Virol, 2013, 87(9), 5300-4.
22. Kumaki, Y.; Day, C.W.; Wandersee, M.K.; Schow, B.P.; Madsen, J.S.; Grant, D.; Roth, J.P.; Smee, D.F.; Blatt, L.M.; Barnard, D.L. Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells. Biochem Biophys Res Commun, 2008, 371(1), 110-13.
23. Barnard, D.L.; Hubbard, V.D.; Smee, D.F.; Sidwell, R.W. In: Inhibition of human coronavirus by antiviral agents: Potential therapies for SARS coronavirus. Proceedings of the 16th International Conference on Antiviral Research, Savannah, Georgia, USA, April 27-May 1, 2003; Abstract # Late Breaker 4.
24. Strayer, D.R; Carter, W.; Strauss, K.I.; Brodsky, I.; Suhadolnik, R.; Ablashi, D.; Henry, B.; Mitchell, W.M.; Bastien, S.; Peterson, D. Long term improvements in Patients with Chronic Fatigue Syndrome Treated with Ampligen. J CFS, 1995, 1, 35-53.
25. Thompson, K.A.; Strayer, D.R.; Salvato, P.D.; Thompson, C.E.; Klimas, N.; Molavi, A.; Hamill, A.K.; Zheng, Z.; Ventura, D.; Carter, W.A. Results of a Double-Blinded Placebo-Controlled Study of the Double-Stranded RNA Drug PolyI:PolyC12U in the Treatment of HIV Infection. Eur J Clin Microbiol Infect Dis, 1996, 15, 580-7.
26. Falzarano, D.; de Wit, E.; Rasmussen, A.L.; Feldmann, F.; Okumura, A.; Scott, D.P.; Brining, D.; Bushmaker, T.; Martellaro, C.; Baseler, L.; Benecke, A.G.; Katze, M.G.; Munster, V.J.; Feldmann, H. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med, 2013, 19(10), 1313-7.
27. Al-Tawfiq, J.A., Momattin, H.; Dib, J.; Memish, Z.A. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis, 2014, 20, 42-6.
28. Pathology Handbook, University of Iowa http://www.healthcare.uiowa.edu/path_handbook/test1087.html
29. Physicians' Desk Reference (PDR.net) http://www.pdr.net/druginformation/myfortic?druglabelid=435
30. Wathelet, M.; Orr, M.; Frieman, M.B.; Baric, R.S. Severe Acute Respiratory Syndrome Coronavirus Evades Antiviral Signaling: Role of nsp1 and Rational Design of an Attenuated Strain. J Virology, 2007, 81(21), 11620-33.
31. Narayanan, K.; Huang, C.; Lokugamage, K.; Kamitani, W.; Ikegami, T.; Tseng, C.T.; Makino, S. Severe Acute Respiratory Syndrome Coronavirus nsp1 Suppresses Host Gene Expression, Including That of Type I Interferon, in Infected Cells. J Virology, 2008, 82(9), 4471-79.
32. Lokugamage, K.G.; Narayanan, K.; Huang, C.; Makino, S. Severe Acute Respiratory Syndrome Coronavirus Protein nsp1 is a Novel Eukaryotic Translation Inhibitor That Represses Multiple Steps of Translation Initiation. J Virology, 2012, 86(24), 13598-608.
33. Siu, K-L.; Kok, K-H.; Ng, M-H.J.; Poon, V.K.M.; Yuen, K-Y; Zheng, B-J; Jin, D-Y. Severe Acute Respiratory Syndrome Coronavirus M Protein Inhibits Type I Interferon Production by Impeding the Formation of TRAF3·TANK·TBK1/IKKϵ Complex. J Biol Chem, 2009, 284(24), 16202-9.
34. Smits, S.L.; de Lang, A; van den Brand, J.M.A.; Leijten, L.M.; van IJcken, W.F.; Eijkemans, M.J.C.; van Amerongen, G.; Kuiken, T.; Andeweg, A.C.; Osterhaus, A.D.M.E.; Haagmans, B.L. Exacerbated Innate Host Response to SARS-CoV in Aged Non-Human Primates. PLoS Pathogens, 2010, 6(2), e1000756.
35. Cameron, M.J.; Ran, L.; Xu, L.; Danesh, A.; Bermejo-Martin, J.F.; Cameron, C.M.; Muller, M.P.; Gold, W.L.; Richardson, S.E.; Poutanen, S.M.; Willey, B.M.; DeVries, M.E.; Fang, Y.; Seneviratne, C.; Bosinger, S.E.; Persad, D.; Wilkinson, P.; Greller, L.D.; Somogyi, R; Humar, A.; Keshavjee, S.; Louie, M.; Loeb, M.B.; Brunton, J.; McGeer, A.J.; Canadian SARS Research Network; Kelvin, D.J. Interferon-Mediated Immunopathological Events Are Associated with Atypical Innate and Adaptive Immune Responses in Patients with Severe Acute Respiratory Syndrome. J Virology, 2007, 81(16), 8692-706.
36. Yang, Y.; Zhang, L.; Geng, H.; Deng, Y.; Huang, B.; Guo, Y.; Zhao, Z.; Tan, W. The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell, 2013, 4(12), 951-61.
37. Sturgill, M.G.; Rashidbaigi, A.; Liao, M.J.; Zhao, X.X.; Hua, J.; Trout, R.; Knill, J.R.; Grasing, K.W. Extravascular administration of interferon alfa-N3 increases serum exposure and 2-5(A) synthetase activity. J Clin Pharmacol, 2000, 40, 606-15.
38. Sarna, G.; Figlin, R.; Bryson, Y.; Garratty, E.; Myers, L.; Le Fevre, C.; Mauritzon, N.; Cline, M. Human alpha-lymphoblastoid interferon. A phase I study including pharmacokinetics and effects on hematologic stem cells (CFU-GMs). Am J Clin Oncol, 1985, 8, 406-12.
39. Falzarano, D.; de Wit, E.; Martellaro, C.; Callison, J.; Munster, V.J.; Feldmann, H. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep, 2013, 3, 1686. doi:10.1038/srep01686.
40. Chen, F.; Chan, K.H.; Jiang, Y.; Kao, R.Y.; Lu, H.T.; Fan, K.W.; Cheng, V.C.; Tsui, W.H.; Hung, I.F.; Lee, T.S.; Guan, Y.; Peiris, J.S.; Yuen, K.Y. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clinical Virol, 2004, 31, 69-75.
41. Ströher, U.; DiCaro, A.; Li, Y.; Strong, J.E.; Aoki, F.; Plummer, F.; Jones, S.M.; Feldmann, H. Severe Acute Respiratory Syndrome- Related Coronavirus Is Inhibited by Interferon-a. J Infect Dis, 2004, 189, 1164-7.
42. Zheng, B.; He, M.L.; Wong, K.L.; Lum, C.T.; Poon, L.L.; Peng, Y.; Guan, Y.; Lin, M.C.; Kung, H.F. Potent inhibition of SARSassociated coronavirus (SCOV) infection and replication by type I interferons (IFN-alpha/beta) but not by type II interferon (IFNgamma). J Interferon Cyt Res, 2004, 24(7), 388-90.
43. Levine, A.; Sivulich, M.; Wiernik, P.; Levy, H. Initial Clinical Trials in Cancer Patients of Polyribosinic-Polyribocytidylic Acid Stabilized with Poly-L-lysine, in Carboxymethylcellulose {Poly(ICLC)}, a Highly Effective Interferon Inducer. Cancer Res, 1979, 39, 1645-50.